BioSpace News Archive

Business

PureTech Health and Roche Sign Collaboration Deal Worth $1 Billion-Plus

Boston-based PureTech Health inked a multi-year collaboration deal with Swiss-based Roche to advance PureTech’s milk-derived exosome platform technology for oral dosing of Roche’s antisense oligonucleotide platform.

July 20, 2018
·
3 min read
·
Mark Terry
Pharm Country

Merck Lowers Price of Some of its Older Drugs; Presidential Pricing Controversy

Merck said it will lower the cost of one drug by 60 percent and several other drugs by 10 percent.

July 20, 2018
·
3 min read
·
Alex Keown
Deals

Rumor Alert: Merck KGaA to Buy Madrigal and Roche to Acquire Tesaro?

Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.

July 20, 2018
·
3 min read
·
Mark Terry
Business

Two Artificial Intelligence Companies Partner to Take on DMD and Orphan Diseases

For many companies, artificial intelligence has become a key tool in drug development. Now, two companies that specialize in AI-backed drug development are teaming up to take on the rare disease known as Duchene Muscular Dystrophy.

July 20, 2018
·
2 min read
·
Alex Keown
FDA

FDA, Trump Administration Explore Importing Foreign Drugs Under Narrow Scope

The U.S. Food and Drug Administration is looking to address supply chain threats by potentially importing foreign drugs under a narrow scope.

July 20, 2018
·
2 min read
·
Alex Keown
Biotech Bay

Sanofi and Roche Take Trump’s No-Drug-Price-Increase Pledge, at Least for Now

It was reported today that U.S.-based Merck & Co. will lower the price of some of its drug. It appears to be rippling through the industry, largely in an attempt to stay out of the way of Trump’s attack-tweets.

July 20, 2018
·
2 min read
·
Mark Terry
Deals

PTC Therapeutics to Buy Agilis Biotherapeutics in Deal that Could Exceed $945 Million

PTC Therapeutics is buying Agilis Biotherapeutics in a deal that has the potential to exceed $945 million.

July 20, 2018
·
2 min read
·
Mark Terry
FDA

Agios Pharmaceuticals Scores FDA Approval For Tibsovo, Second AML Drug Win in Less Than a Year

Shares of Agios Pharmaceuticals jumped this morning after the company said the FDA approved its oral leukemia treatment Tibsovo (ivosidenib). It’s the second approval for the company in less than a year.

July 20, 2018
·
2 min read
·
Alex Keown
Business

With Patent Win in Hand, Novartis Files Lawsuits Against Would-be Gilenya Competitors

Last year, Novartis’ multiple sclerosis drug Gilenya generated more than $3 billion in revenue, with a little more than half of that coming from sales in the United States. As the drug faces patent loss in the future, Novartis is fighting to preserve that revenue driver with multiple lawsuits.

July 20, 2018
·
2 min read
·
Alex Keown
Business

PureTech Health Announces Collaboration with Roche to Advance Technology for Oral Administration of Antisense Oligonucleotides

PureTech Health to receive up to $36 million in upfront payments, research support, and early preclinical milestones and is eligible to potentially receive over $1 billion in development milestones

July 20, 2018
·
5 min read